FROM A-LEVELS OR AN OVERSEAS DEGREE TO PRACTISING IN THE UKSearch the guide
← All news
NEW MEDICINES AND DRUG DISCOVERY · FDA: DRUGS · 30 October 2026

E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs

Synopsis

Guidance Issuing OfficeCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research If unable to submit comments online, please mail written comments to:

Automatically extracted from the original page. This is a short summary, not the full story, and may omit important detail.

Read the full story at FDA: drugs ↗

More in New medicines and drug discovery